Fig. 3.

Proportion of patients who achieved DAS28-CRP defined as low disease activity (LDA), clinical remission, good or moderate EULAR response, and good EULAR response. *p < 0.05; **p < 0.01. ABT abatacept, ADA adalimumab, TCZ tocilizumab, EULAR European League Against Rheumatism